ICVX NASDAQ
Seattle, WA 98102
US
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMEN | D-Return | 17,000 | $9.89 | 2024-02-19 |
| RA CAPITAL MANAGEMEN | U-Tender | 638,668 | $15.00 | 2024-02-19 |
| RA CAPITAL MANAGEMEN | D-Return | 22,278 | $6.25 | 2024-02-19 |
| Simpson Adam K. | U-Tender | 129,032 | $15.00 | 2024-02-19 |
| Simpson Adam K. | D-Return | 317,866 | $17.55 | 2024-02-19 |